Merck & Co., Inc.
NYSE:MRKDrug Manufacturers - General
-$1.32 today
- Market cap
- $339.66B
- Beta
- 0.22
- P/E (TTM)
- 31.6
- EPS (TTM)
- $3.61
- Dividend yield
- 2.94%
Volume 9.69M
Average 11.85M
MRK EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Merck & Co., Inc.NYSE: MRK
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA declines year over year
Q2 FY2026 EBITDA of $1.43B fell 77.8% year over year, behind the -44.4% change in trailing-twelve-month EBITDA. Over 3 fiscal years it compounded at +9.9% a year.
Context
- EBITDA amounted to 43.5% of revenue in FY2025, up 3.5 pp from a year earlier.
- EBITDA increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 18 analysts of $16.09B (-43.1%) for the fiscal year ending Dec 2026, a slowdown from the +9.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $1.43B+170.5% QoQ
- Last fiscal yearDec 2025
- $28.26B+9.9% YoY
- LTMJun 2026
- $13.93B-44.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -77.8% | +9.8% | +87.6 pp |
| 1 year | +9.9% | -43.1% | -53.0 pp |
| 3-year CAGR | +9.9% | +11.7% | +1.8 pp |
| 5-year CAGR | +6.9% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 28.26B USD
- Year-over-year change
- +9.9%
- 4-year CAGR
- +12.1%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.26B | +9.9% |
| FY2024 | 2024-12-31 | 25.71B | +272.2% |
| FY2023 | 2023-12-31 | 6.91B | -67.6% |
| FY2022 | 2022-12-31 | 21.32B | +19.1% |
| FY2021 | 2021-12-31 | 17.9B | — |
EBITDA vs competitors
How MRK compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -44.4% is the 9th highest of 10, against a peer median of +10.8%.
- EBITDA amounts to 21.0% of revenue for MRK, versus a peer median of 34.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $43.3B USD | +103.7% | +54.1% | 54.4% | |
| LTM Sep 2026 | $30.81B USD | -22.1% | +15.6% | 31.0% | |
| LTM Sep 2026 | $24.15B USD | +88.7% | -10.0% | 36.6% | |
| LTM Jun 2026 | $22.26B USD | -2.0% | +16.1% | 40.0% | |
| LTM Sep 2026 | $21.37B USD | +18.6% | +29.7% | 34.4% | |
| LTM Jun 2026 | $17.62B USD | +10.8% | +11.6% | 46.2% | |
| LTM Jun 2026 | €14.77B EUR | +15.5% | -2.6% | 30.2% | |
| LTM Jun 2026 | $13.93B USD | -44.4% | +9.9% | 21.0% | |
| LTM Jun 2026 | $13.49B USD | -33.1% | -25.8% | 21.2% | |
| LTM Jun 2026 | $1.33B USD | -87.8% | +15.3% | 4.4% | |
| Peer median (excluding MRK) | — | +10.8% | +15.3% | 34.4% | |
Competitors are the stored peer set for MRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.7B | 59.28B | 60.12B | 64.17B | 64.93B |
| Cost of Revenue | 13.63B | 17.41B | 16.13B | 15.19B | 18.2B |
| Gross Profit | 35.08B | 41.87B | 43.99B | 48.98B | 46.73B |
| Gross Margin | 72.0% | 70.6% | 73.2% | 76.3% | 72.0% |
| Research & Development | 12.25B | 13.55B | 30.53B | 17.94B | 12.51B |
| Selling, General & Admin | 9.4B | 9.67B | 9.88B | 10.1B | 10.73B |
| Operating Expenses | 21.88B | 23.59B | 41.04B | 28.75B | 23.25B |
| Depreciation & Amortization | 3.21B | 3.91B | 3.87B | 4.5B | 5.84B |
| EBITDA | 17.9B | 21.32B | 6.91B | 25.71B | 28.26B |
| EBITDA Margin | 36.8% | 36.0% | 11.5% | 40.1% | 43.5% |
| Operating Income | 13.2B | 18.28B | 2.95B | 20.22B | 23.49B |
| Operating Margin | 27.1% | 30.8% | 4.9% | 31.5% | 36.2% |
| Interest Income | 36M | 157M | 365M | 415M | 343M |
| Interest Expense | 806M | 962M | 1.15B | 1.27B | 1.36B |
| Other Income / Expenses | 680M | (1.84B) | (1.07B) | (285M) | (2.42B) |
| Income Before Tax | 13.88B | 16.44B | 1.89B | 19.94B | 21.07B |
| Pre-Tax Margin | 28.5% | 27.7% | 3.1% | 31.1% | 32.4% |
| Income Tax Expense | 1.52B | 1.92B | 1.51B | 2.8B | 2.8B |
| Net Income | 13.05B | 14.52B | 365M | 17.12B | 18.25B |
| Net Margin | 26.8% | 24.5% | 0.6% | 26.7% | 28.1% |
| EPS (Basic) | 5.16 | 5.73 | 0.14 | 6.76 | 7.30 |
| EPS (Diluted) | 5.14 | 5.71 | 0.14 | 6.74 | 7.28 |
| Weighted Avg Shares | 2.53B | 2.53B | 2.55B | 2.53B | 2.5B |
| Weighted Avg Shares (Diluted) | 2.54B | 2.54B | 2.55B | 2.54B | 2.51B |
Merck & Co., Inc.
NYSE:MRK
Intrinsic Alpha fair value
Locked
Current Price
$137.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.